CCN2 and myocardial ischemia: While CTGF monoclonal antibody treatment apparently improved survival and reduced left ventricular dysfunction, hypertrophy, and fibrosis after cardiac ischemia and during post-AMI remodeling, CTGF antagonism had no effect on CM viability and infarct size following IR injury (Vainio et al., 2019).